Highlights and Quick Summary
- EBIT Margin for the quarter ending September 30, 2022 was -38200.0% (a 35036.13% increase compared to previous quarter)
- Year-over-year quarterly EBIT Margin increased by 2872.25%
- Annual EBIT Margin for 2021 was -1654.23% (a -85.62% decrease from previous year)
- Annual EBIT Margin for 2020 was -11503.99% (a 776.28% increase from previous year)
- Annual EBIT Margin for 2019 was -1312.82% (a -Infinity% decrease from previous year)
- Twelve month EBIT Margin ending September 30, 2022 was -618.72% (a -1.4% decrease compared to previous quarter)
- Twelve month trailing EBIT Margin decreased by -25.2% year-over-year
Trailing EBIT Margin for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| -618.72% | -627.51% | -821.46% | -827.12% |
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Margin of BridgeBio Pharma, Inc.
Most recent EBIT Marginof BBIO including historical data for past 10 years.Interactive Chart of EBIT Margin of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | -38200.0% | -108.72% | -10252.54% | – |
| 2021 | -1285.22% | -6377.94% | -174.02% | -36256.28% | -1654.23% |
| 2020 | -104499.18% | -1475.81% | 0.0% | 0.0% | -11503.99% |
| 2019 | -569.06% | -203.93% | 0.0% | 0.0% | -1312.82% |
| 2018 | – | – | – | 0.0% | 0.0% |
| 2017 | – | – | – | – | 0.0% |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology